P/E at 30.58 vs Industry's 36.72: What the Data Shows for Dr Reddys Laboratories Ltd

2 hours ago

Share Via

A price-to-earnings ratio of 30.58 against an industry average of 36.72 reveals a notable valuation discount for Dr Reddys Laboratories Ltd. Previously rated Hold by MarketsMojo, the stock’s rating was reassessed on 13 Jul 2026. While the one-year return of -5.20% slightly outperforms the Sensex’s -5.52%, the recent three-month performance paints a starkly different picture with a sharp decline of -11.50% versus the Sensex’s positive 2.57%. The data presents a complex narrative of valuation and momentum that investors must carefully analyse.

Valuation Picture: Discount Amidst Sector Premiums

Dr Reddys Laboratories Ltd trades at a P/E multiple of 30.58, which is approximately 16.7% below the Pharmaceuticals & Biotechnology industry average of 36.72. This discount suggests that the market currently values the company’s earnings less generously than its peers. Such a valuation gap can imply either perceived risks or underappreciated opportunities within the stock. The sector’s elevated P/E reflects growth expectations and premium pricing for innovation and pipeline potential, but Dr Reddys Laboratories Ltd appears to be trading with a more cautious sentiment. Previously rated Hold, what is Dr Reddys Laboratories Ltd’s current rating? The valuation premium or discount is a critical factor in this reassessment.

Performance Across Timeframes: Divergent Momentum

The stock’s performance over the past year has been marginally better than the Sensex, with a decline of -5.20% compared to the benchmark’s -5.52%. However, this relative resilience masks a more troubling short-term trend. Over the last three months, Dr Reddys Laboratories Ltd has fallen by -11.50%, significantly underperforming the Sensex’s 2.57% gain. This sharp divergence indicates a loss of momentum and possibly growing investor concerns or sector-specific headwinds. The one-month and one-week returns of -2.51% and -1.54% respectively also lag behind the Sensex’s -1.30% and -1.06%, reinforcing the recent weakness. Is this a temporary setback or a sign of deeper structural challenges? The data suggests the former resilience is giving way to a more pronounced downtrend.

Moving Average Configuration: Bearish Technical Setup

Technically, Dr Reddys Laboratories Ltd is trading below all major moving averages — the 5-day, 20-day, 50-day, 100-day, and 200-day. This comprehensive positioning below short, medium, and long-term averages signals a bearish trend and suggests the stock is in a sustained downtrend rather than a transient correction. The absence of any recent recovery above these averages indicates that the stock has yet to find a technical foothold. The four-day consecutive fall, resulting in a cumulative decline of -4.41%, further emphasises the downward pressure. The stock’s opening gap down of -2.35% on the latest trading day and intraday low of Rs 1152.8 reinforce this negative momentum. The 5% surge partially reverses a 6.45% monthly decline — is this a genuine recovery or a relief rally that will fade at the 50 DMA? The moving average configuration provides the clearest answer.

Sector Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen a mixed bag of results recently, with 34 stocks having declared results so far. Of these, 14 reported positive outcomes, 15 were flat, and 5 posted negative results. This distribution suggests a sector grappling with uneven growth and profitability pressures. Dr Reddys Laboratories Ltd’s performance and valuation must be viewed against this backdrop of sector volatility. The stock’s mid-cap market capitalisation of approximately Rs 98,533.48 crore places it among the larger players, yet its recent underperformance relative to the sector’s mixed results raises questions about its competitive positioning. Should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider? The current rating provides the answer.

Rating Reassessment: From Hold to a New Evaluation

On 13 Jul 2026, the rating for Dr Reddys Laboratories Ltd was updated from Hold to a new assessment. While the precise current grade is not disclosed, the change reflects a reassessment of the company’s fundamentals and market positioning. The previous Mojo Score of 30.0 and the mid-cap market cap grade provide context for this shift. The rating update likely factors in the valuation discount, recent negative momentum, and the bearish technical setup. What is the current rating for Dr Reddys Laboratories Ltd following this reassessment? This question remains central to understanding the stock’s outlook.

Conclusion: A Complex Data-Driven Picture

The data on Dr Reddys Laboratories Ltd reveals a stock trading at a valuation discount relative to its sector, yet facing significant short-term performance challenges and a bearish technical configuration. The one-year return slightly outperforms the Sensex, but the recent three-month decline of -11.50% signals a loss of momentum. Trading below all major moving averages and enduring a four-day consecutive fall underscores the prevailing downtrend. The sector’s mixed results add further complexity to the stock’s outlook. Should investors consider holding, adding, or exiting their position in Dr Reddys Laboratories Ltd? The updated rating and comprehensive data analysis provide essential insights for this decision.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)

MOJO SCORE